BridgePoint Bio
We are living in a biological renaissance.
New categories, or modalities, of medicine allow precise delivery of targeted therapies to specific tissues in the human body. These modalities include: RNA therapies, gene-editing, AAV gene therapy, CAR-T, cell therapy, ADCs and bispecific antibodies. In our educational seminars, we explore the historical, scientific and commercial context of these new medical treatments.
- We function as a science advisor and perform research on specific topics.
- We design, build and deliver educational courses for life-science companies.
- Our seminars explore clinical, commercial and manufacturing issues.
- Courses are taught in-person or remotely on zoom.
Our educational courses help build culture and community around biotech organizations. The BridgePoint teaching style encourages questions, audience engagement and back-and-forth dialogue. Our presentations provide an opportunity for all employees at a life science company to understand the mechanics of advanced medicines. Bridgepoint webinars can be utilized as an outreach tool into a biotech company’s broader ecosystem of customers, clients and partners.
Subscribe to our BridgePoint YouTube page to watch our weekly videos.
- Our videos provide biological context around breaking news stories in advanced medicine. We highlight key takeaways and insights surrounding new clinical or commercial developments in genetic medicine.
BridgePoint Bio is a biotech consulting firm founded by Kevin Curran PhD.
Kevin is a molecular biologist and former University of San Diego professor.
- PhD in molecular biology (Univ. of Washington, Seattle): research on stem cell biology and neural crest development
- Post-doctorate work at Salk Institute (San Diego): research on the neuroscience of fear and anxiety
For the past 10 years, Kevin has worked as an educator and science consultant throughout the biotech and pharma industry.
Recent clients: Bristol Meyers Squibb, BioMarin, Healthpeak Properties, Biogen, Genentech, Stanford University, Juno Therapeutics, Sarepta, Emergent BioSolutions, Pfizer, AbbVie and Eli Lily.